Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Company profile
Ticker
LXRX
Exchange
Website
CEO
Dr. Michael Exton Ph.D.
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
LEXICON GENETICS INC/TX, LEXICON PHARMACEUTICALS, INC./DE
SEC CIK
Corporate docs
Subsidiaries
Lexicon Pharmaceuticals (New Jersey), Inc. ...
IRS number
760474169
LXRX stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
16 Oct 24
8-K
Departure of Directors or Certain Officers
16 Sep 24
EFFECT
Notice of effectiveness
16 Aug 24
S-3
Shelf registration
2 Aug 24
10-Q
2024 Q2
Quarterly report
2 Aug 24
8-K
Lexicon Pharmaceuticals Reports Second Quarter 2024
1 Aug 24
8-K
Departure of Directors or Certain Officers
8 Jul 24
8-K
Entry into a Material Definitive Agreement
1 Jul 24
EFFECT
Notice of effectiveness
16 May 24
S-3/A
Shelf registration (amended)
10 May 24
Transcripts
LXRX
Earnings call transcript
2024 Q2
1 Aug 24
LXRX
Earnings call transcript
2024 Q1
2 May 24
LXRX
Earnings call transcript
2023 Q3
8 Nov 23
LXRX
Earnings call transcript
2023 Q2
3 Aug 23
LXRX
Earnings call transcript
2023 Q2
3 Aug 23
LXRX
Earnings call transcript
2023 Q1
2 May 23
LXRX
Earnings call transcript
2022 Q4
2 Mar 23
LXRX
Earnings call transcript
2022 Q3
10 Nov 22
LXRX
Earnings call transcript
2022 Q2
3 Aug 22
LXRX
Earnings call transcript
2022 Q1
5 May 22
Latest ownership filings
3
Lisa DeFrancesco
7 Oct 24
144
Notice of proposed sale of securities
15 Aug 24
4
Brian Corrigan
12 Aug 24
3
Brian Corrigan
12 Aug 24
SC 13D/A
Invus, L.P.
29 Jul 24
3
Initial statement of insider ownership
29 Jul 24
SC 13G
FMR LLC
10 Jul 24
4
JEFFREY L WADE
8 Jul 24
4
Michael Exton
8 Jul 24
3
Michael Exton
8 Jul 24
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 35.62 mm | 35.62 mm | 35.62 mm | 35.62 mm | 35.62 mm | 35.62 mm |
Cash burn (monthly) | 20.29 mm | 5.55 mm | 18.45 mm | 16.42 mm | 16.18 mm | 16.32 mm |
Cash used (since last report) | 80.90 mm | 22.15 mm | 73.56 mm | 65.47 mm | 64.51 mm | 65.06 mm |
Cash remaining | -45.29 mm | 13.47 mm | -37.95 mm | -29.85 mm | -28.89 mm | -29.45 mm |
Runway (months of cash) | -2.2 | 2.4 | -2.1 | -1.8 | -1.8 | -1.8 |
Institutional ownership, Q2 2024
13F holders | Current |
---|---|
Total holders | 130 |
Opened positions | 30 |
Closed positions | 16 |
Increased positions | 48 |
Reduced positions | 20 |
13F shares | Current |
---|---|
Total value | 470.54 bn |
Total shares | 470.22 mm |
Total puts | 286.10 k |
Total calls | 617.10 k |
Total put/call ratio | 0.5 |
Largest owners | Shares | Value |
---|---|---|
Artal | 175.10 mm | $294.17 bn |
Invus | 175.10 mm | $313.43 mm |
FMR | 38.69 mm | $64.99 bn |
Biotechnology Value Fund L P | 16.15 mm | $0.00 |
BLK BlackRock | 9.89 mm | $16.62 bn |
Braidwell | 8.29 mm | $13.94 bn |
Vanguard | 7.68 mm | $12.89 bn |
Orbimed Advisors | 5.85 mm | $9.82 bn |
Point72 Asset Management | 4.12 mm | $6.92 bn |
Geode Capital Management | 3.25 mm | $5.46 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Aug 24 | Brian Corrigan | Stock Option Common Stock | Grant | Acquire A | No | No | 1.6 | 200,000 | 320.00 k | 200,000 |
News
Deep Dive Into Lexicon Pharmaceuticals Stock: Analyst Perspectives (9 Ratings)
23 Oct 24
HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $10 Price Target
23 Oct 24
Lexicon Announces Completion Of Screening In Phase 2B Progress Study Of LX9211 In Diabetic Peripheral Neuropathic Pain
22 Oct 24
Peeling Back The Layers: Exploring Lexicon Pharmaceuticals Through Analyst Insights
17 Oct 24
HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $10 Price Target
17 Oct 24
Press releases
Lexicon Announces Completion of Screening in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
22 Oct 24
Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe
16 Oct 24
Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe
16 Oct 24
Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress
27 Sep 24
New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes
10 Sep 24